Therapies
Friday, March 22nd, 2013
International Journal of Stroke: March 19, 2013 Background and purpose Heart failure is an independent risk factor for stroke. Anticoagulation is effective for prevention of cardio-embolic stroke secondary to atrial fibrillation or mechanical heart valves but is of uncertain benefit in heart failure patients. We performed this meta-analysis to obtain the best estimates of the […]
Therapies
Friday, March 22nd, 2013
STROKEAHA: March 19, 2013 Background and Purpose—Self-expanding stents are increasingly used for treatment of complex intracranial aneurysms. We assess the safety and the efficacy of intracranial stenting and determine predictors of treatment outcomes. Methods—A total of 508 patients with 552 aneurysms were treated with Neuroform and Enterprise stents between 2006 and 2011 at our institution. A […]
Therapies
Friday, March 22nd, 2013
STROKEAHA: March 14, 2013 Background and Purpose—Symptomatic intracerebral hemorrhage (sICH) after tissue plasminogen activator for acute ischemic stroke is associated with poor outcome. There are conflicting data on sICH risk related to lipid levels and use of lipid-lowering medications. We evaluated whether there are associations between lipid levels, lipid-lowering medications, and sICH in Get With the […]
Therapies
Friday, March 22nd, 2013
STROKEAHA: March 14, 2013 Background and Purpose—To evaluate the impact of proximal flow control on efficacy and safety of mechanical thrombectomy in an in vitro middle cerebral artery occlusion. Methods—Three independent variables, including clot type, device (Merci Retriever, Solitaire FR, and Trevo devices), and use of a balloon guide catheter, were used to ascertain the impact […]
News
Friday, March 22nd, 2013
JAMA: March 20, 2013 Importance Long-term data on mortality after first-ever stroke in adults aged 18 through 50 years are scarce and usually restricted to ischemic stroke. Moreover, expected mortality not related to first-ever stroke is not taken in account. Objectives To investigate long-term mortality and cause of death after acute stroke in adults aged 18 […]
News
Friday, March 22nd, 2013
International Journal of Stroke: March 19, 2013 Background No commonly agreed definition exists for ‘stroke symptom knowledge’ among members of the general public. Recalling at least one correct stroke symptom has been used in the past. However, this criterion was not associated with rapid presentation to hospital. Rapid presentation is vital in order to provide […]
News
Friday, March 22nd, 2013
Cardiology News: March 19, 2013 Health care reformers looking to drive down preventable 30-day readmission rates will find slim pickings among the nation’s elderly hospitalized for ischemic stroke, according to Judith H. Lichtman, Ph.D. An analysis of national fee-for-service Medicare data concluded that a mere 1.7% of patients hospitalized for ischemic stroke in 2006 had […]
News
Friday, March 22nd, 2013
STROKEAHA: March 14, 2013 Background and Purpose—To evaluate cerebral microbleeds (CMBs) and future stroke risk (including intracerebral hemorrhage [ICH]) in patients with ischemic stroke (IS) or transient ischemic attack. Materials and Methods—A systematic review and meta-analysis of prospective cohorts with recent IS/transient ischemic attack. We critically appraised studies and calculated pooled odds ratios (ORs), using the […]
Atrial Fibrillation
Thursday, March 14th, 2013
NEJM: March 13, 2013 In the months following the approval of the oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) in October 2010, the Food and Drug Administration (FDA) received through the FDA Adverse Event Reporting System (FAERS) many reports of serious and fatal bleeding events associated with use of the drug. Because dabigatran is an anticoagulant, […]
Atrial Fibrillation
Thursday, March 14th, 2013
STROKEAHA: March 12, 2013 Background and Purpose—Although oral anticoagulants (OACs) are highly effective in reducing stroke risk in atrial fibrillation, some patients still sustain stroke despite being on an OAC. Our aim was to identify the risk factors that contribute to stroke risk in atrial fibrillation, although patients were taking OACs in a clinical trial setting. […]
